AE	adverse effect
ACE	angiotensin-converting enzyme
AKT	protein kinase B
ARB	angiotensin receptor blocker
AXL	tyrosine-protein kinase receptor UFO
BAA	beta-adrenoceptor antagonist
BAD	BCL2 associated agonist of cell death
BP	blood pressure
CCB	calcium channel blocker
CVD	cardiovascular disease
CO	cardiac output
EFGR	epidermal growth factor receptor
ERK	extracellular regulated kinase
ET-1	endothelin-1
FDA	food and drug administration
FLT-3	fms-like tyrosine kinase 3
GF	growth factor
HGF	hepatocyte growth factor
HR	hazard ration
KIT	tyrosine-protein kinase KIT or CD117
MAP	mean arterial pressure
MAPK	mitogen-activated protein kinase
MDM2	mouse double minute 2
MEK	mitogen-activated protein kinase kinase-1
MET	mesenchymal-epithelial transition
MET	tyrosine-protein kinase Met or hepatocyte growth factor receptor
TKI	multi-kinase inhibitor
MTC	medullary thyroid cancer
mTOR	mammalian target of rapamycin
NO	nitric oxide
NTRK-2	neurotrophic tyrosine receptor kinase 2
OS	overall survival
PDGF	platelet-derived growth factor
PGI2	prostaglandins
PI3K	phosphoinositide 3 kinases
PFS	progression-free survival
RAF	rapidly accelerated fibrosarcoma
RAS	rat sarcoma
RECIST	Response Evaluation Criteria in Solid Tumors
RET	rearranged during transfection
RTK	receptor tyrosine kinase
TC	thyroid cancer
TIE-2	angiopoietin-1 receptor
TRKB	tropomyosin receptor kinase B
TRP	total peripheral resistance
VEGF	vascular endothelial growth factor
VEGFR	vascular endothelial growth factor receptor
VS	versus